1800 related articles for article (PubMed ID: 25728496)
1. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
2. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
[TBL] [Abstract][Full Text] [Related]
3. Apixaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Li XM; Sun SG; Zhang WD
Chin Med J (Engl); 2012 Jul; 125(13):2339-45. PubMed ID: 22882859
[TBL] [Abstract][Full Text] [Related]
4. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Huang J; Cao Y; Liao C; Wu L; Gao F
Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
[TBL] [Abstract][Full Text] [Related]
5. Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Squizzato A; Lussana F; Cattaneo M
Thromb Haemost; 2015 Aug; 114(2):237-44. PubMed ID: 25946985
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
7. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus enoxaparin in the prevention of venous thromboembolism following total knee arthroplasty: a single-centre, single-surgeon, retrospective analysis.
King DA; Pow RE; Dickison DM; Vale PR
Intern Med J; 2016 Sep; 46(9):1030-7. PubMed ID: 27246450
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
[TBL] [Abstract][Full Text] [Related]
11. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
Ning GZ; Kan SL; Chen LX; Shangguan L; Feng SQ; Zhou Y
Sci Rep; 2016 Mar; 6():23726. PubMed ID: 27020475
[TBL] [Abstract][Full Text] [Related]
14. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
15. The role of apixaban for venous and arterial thromboembolic disease.
Prom R; Spinler SA
Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
[TBL] [Abstract][Full Text] [Related]
16. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Hornick P;
Lancet; 2010 Mar; 375(9717):807-15. PubMed ID: 20206776
[TBL] [Abstract][Full Text] [Related]
17. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R
Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051
[TBL] [Abstract][Full Text] [Related]
18. Apixaban or enoxaparin for thromboprophylaxis after knee replacement.
Lassen MR; Raskob GE; Gallus A; Pineo G; Chen D; Portman RJ
N Engl J Med; 2009 Aug; 361(6):594-604. PubMed ID: 19657123
[TBL] [Abstract][Full Text] [Related]
19. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Robertson L; Kesteven P; McCaslin JE
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644
[TBL] [Abstract][Full Text] [Related]
20. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Feng W; Wang X; Huang D; Lu A
Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]